HIV Infection: Clinical Trials

87 trials for HIV Infection, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

60 completed, 11 terminated, 8 unknown, 4 recruiting. 87 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 487Completed 60, Terminated 11, Unknown 8, Recruiting 4, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1

Follow HIV Infection: new trials by email Literature Review of HIV Infection trials Research Report on HIV Infection

Trials (filtered) newest first · largest first

All 87 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI Study
Field-based LA-CAB/RPV - HIV Infection
Phase 4Not yet recruitingUniversity of North Carolina, Chapel Hill402027-01-012026-10-26
Menopausal HT for Women Living With HIV (HoT)
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel - HIV Infection, Menopause
Phase 4RecruitingAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1052026-04-092026-05-22
MAPS PrEP Van Study
Pre-Exposure Prophylaxis (PrEP) - HIV Infection
Phase 4CompletedDuke University72025-09-172026-07-24
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
Dual therapy: darunavir/cobicistat + lamivudine, Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine - HIV Infection, Antiretroviral Therapy
Phase 4RecruitingInstituto Mexicano del Seguro Social782025-07-102026-07-01
Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience
DTG/3TC, Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF) - HIV Infection, Metabolic Syndrome
Phase 4RecruitingInstituto Mexicano del Seguro Social1242025-04-012025-06-26
Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation
Regimen:BIC+FTC+TAF - HIV Infection, HIV
Phase 4Not yet recruitingNational Center for AIDS/STD Control and Prevention, China CDC2502025-02-282025-02-17
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico
dual therapy, Standard Medical Therapy - HIV Infection
Phase 4RecruitingJosé Antonio Mata Marín1382023-11-092025-04-04
Utilizing Private Pharmacies to Initiate High-risk Young Individuals on PrEP in South Africa
Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC) - HIV Infection
Phase 4Active not recruitingProfessor Francois Venter19002023-05-192025-06-05
Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial
Recombinant Human Papillomavirus Nonavalent Vaccine - HIV Infection
Phase 4CompletedFred Hutchinson Cancer Center972022-03-102026-07-02
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy
Dihydroartemisinin-piperaquine - Drug-Drug Interaction, HIV Infection
Phase 4CompletedUniversity of California, San Francisco1942020-11-232025-03-14
Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
Estradiol Vaginal Insert - HIV Infection, Vaginal Atrophy
Phase 4CompletedKerry Murphy602020-09-012025-03-14
Triple vs. Double Therapy in naïves HIV-Infected Patients
Randomize - HIV Infection
Phase 4UnknownHospitales Universitarios Virgen del Rocío702020-03-102020-08-18
Nevirapine / Lamivudine for HIV Maintenance Therapy
Neviparine (NVP)/ Lamivudine (3TC) - HIV Infection, Antiretroviral Treatment
Phase 4CompletedCantonal Hospital of St. Gallen2012019-04-122025-06-10
Linking Infectious and Narcology Care-Part II
Rapid ART initiation, Pharmacotherapy for opioid use disorder, Strengths-based HIV case management - HIV Infection, Drug Use
Phase 4CompletedBoston Medical Center2252018-09-192023-04-18
RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection
Rilpivirine + darunavir/cobicistat - HIV Infection
Phase 4UnknownA.O. Ospedale Papa Giovanni XXIII16092017-02-012019-08-22
Liraglutide for HIV-associated Neurocognitive Disorder
Liraglutide - HIV Infection, Diabetes Mellitus Type 2
Phase 4TerminatedTemple University42016-09-012022-07-29
Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients
PCV13, PPV23 - HIV Infection
Phase 4UnknownAghia Sophia Children's Hospital of Athens402015-12-012017-02-02
Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy
Treatment simplification - HIV Infection
Phase 4CompletedUniversity of British Columbia102014-10-012017-11-06
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
raltegravir and atazanavir and ritonavir, tenofovir/emtricitabine and atazanavir and ritonavir - HIV Infection, Osteopenia
Phase 4TerminatedGiovanni Di Perri42014-09-012018-10-17
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study
Sofosbuvir, Ribavirin, and Stribild - Hepatitis C Infection, HIV Infection
Phase 4CompletedSaint Michael's Medical Center102014-07-012016-08-04

Showing 20 of 87. Sign in to see all of them.

Narrower conditions

HIV Infections (87)  ·  Acquired Immunodeficiency Syndrome (8)  ·  Hepatitis C (3)  ·  Lipodystrophy (3)  ·  Tuberculosis (3)  ·  Cardiovascular Diseases (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Dyslipidemias (2)  ·  Hepatitis B (2)  ·  Hepatitis C, Chronic (2)  ·  Infections (2)  ·  Malaria (2)  ·  Metabolic Syndrome (2)  ·  Aging, Premature (1)  ·  Atherosclerosis (1)

Broader conditions

Blood-Borne Infections (87)  ·  Communicable Diseases (87)  ·  Genital Diseases (87)  ·  Immunologic Deficiency Syndromes (87)  ·  Retroviridae Infections (87)  ·  Sexually Transmitted Diseases (87)  ·  Urogenital Diseases (87)  ·  Immune System Diseases (86)  ·  Lentivirus Infections (86)  ·  RNA Virus Infections (86)  ·  Sexually Transmitted Diseases, Viral (86)  ·  Virus Diseases (86)  ·  Infections (85)  ·  Metabolic Diseases (9)  ·  Nutritional and Metabolic Diseases (9)

Interventions

Tenofovir (10)  ·  Ritonavir (9)  ·  efavirenz (9)  ·  Emtricitabine (8)  ·  Lamivudine (8)  ·  Raltegravir Potassium (8)  ·  Lopinavir (7)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (6)  ·  Atazanavir Sulfate (5)  ·  lopinavir-ritonavir drug combination (5)  ·  Maraviroc (4)  ·  abacavir (4)  ·  abacavir, lamivudine drug combination (4)  ·  Antiretroviral Therapy, Highly Active (3)  ·  Darunavir (3)

Sponsors

GlaxoSmithKline (5)  ·  Fundacion SEIMC-GESIDA (4)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3)  ·  Hospital Clinic of Barcelona (3)  ·  University of British Columbia (3)  ·  University of California, San Francisco (3)  ·  University of Washington (3)  ·  Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2)  ·  Instituto Mexicano del Seguro Social (2)  ·  International Maternal Pediatric Adolescent AIDS Clinical Trials Group (2)  ·  Pfizer (2)  ·  Sociedad Andaluza de Enfermedades Infecciosas (2)  ·  St Stephens Aids Trust (2)  ·  Tufts University (2)  ·  University of North Carolina, Chapel Hill (2)

Countries

United States (33)  ·  Spain (17)  ·  Brazil (8)  ·  Uganda (8)  ·  Canada (6)  ·  Italy (6)  ·  Switzerland (6)  ·  Mexico (5)  ·  Netherlands (5)  ·  Peru (5)  ·  Puerto Rico (5)  ·  South Africa (5)  ·  United Kingdom (5)  ·  Australia (4)  ·  Haiti (4)

Top investigators

Christine A Wanke, MD (2)  ·  Federico Pulido, MD (2)  ·  Felipe Garcia, PhD (2)  ·  Abdel Babiker, PhD (1)  ·  Adeodata Kekitiinwa (1)  ·  Amy Justice, MD, PhD (1)  ·  Ana Puga, MD (1)  ·  Andrea De Luca, Prof (1)  ·  Andy IM Hoepelman, MD (1)  ·  Ann Duerr, MD, PhD (1)  ·  Anna Wald, MD, MPH (1)  ·  Barbara Moscicki, MD (1)

Results publications

PMID 11813503, PMID 11915000, PMID 18097218, PMID 18256392, PMID 18697216, PMID 19349870, PMID 19358725, PMID 19532059, PMID 19542866, PMID 19581631, PMID 19906626, PMID 21350366, PMID 21384334, PMID 21419775, PMID 21422117, PMID 21951596, PMID 21998479, PMID 22010914, PMID 22228003, PMID 22405335, PMID 22848378, PMID 22918156, PMID 23277897, PMID 23362296, PMID 23386261, PMID 23589670, PMID 23646111, PMID 24988179, PMID 25582793, PMID 25711317, PMID 25711318, PMID 25711319, PMID 25711320, PMID 25711321, PMID 25711322, PMID 25711323, PMID 25711324, PMID 25711325, PMID 25711326, PMID 25711327, PMID 25711328, PMID 25711329, PMID 25711330, PMID 25711331, PMID 25711332, PMID 26062880, PMID 26062881, PMID 26192873, PMID 26908541, PMID 26994089

NIH funding

2008 (3), U01AI068632 (2), U01AI068636 (2), 2014 (1), 2019 (1), K23AG062400 (1), K23AI070078 (1), K23DK079789 (1), P30AI064518 (1), R01DA013806 (1), R01DA045547 (1), R01HD068174 (1), R01HL096585 (1), R01MH095507 (1), R34MH139436 (1)